apc 052 Search Results


1 ap rabbit anti hcn4 alomone labs cat  (Alomone Labs)
96
Alomone Labs 1 ap rabbit anti hcn4 alomone labs cat
1 Ap Rabbit Anti Hcn4 Alomone Labs Cat, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1 ap rabbit anti hcn4 alomone labs cat/product/Alomone Labs
Average 96 stars, based on 1 article reviews
1 ap rabbit anti hcn4 alomone labs cat - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
primary anti mouse cd73 apc conjugated antibody  (Miltenyi Biotec)
94
Miltenyi Biotec primary anti mouse cd73 apc conjugated antibody
Primary Anti Mouse Cd73 Apc Conjugated Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary anti mouse cd73 apc conjugated antibody/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
primary anti mouse cd73 apc conjugated antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
rabbit anti hcn4  (Alomone Labs)
94
Alomone Labs rabbit anti hcn4
qRT-PCR measurements reveal downregulation of HCN1 expression in 4W NPY- versus 4W Veh-treated BLA. A, HCN1 mRNA expression in 2W and 4W BLA. HCN1 expression was significantly reduced in the BLA of NPY-treated animals at 4W (2-way ANOVA; treatment: F(1,19) = 4.592, p = 0.04; Time: F(1,19) = 1.348, p = 0.26; interaction: F(1,19) = 5.078, p = 0.03). B, HCN2 expression in 2W and 4W BLA (2-way ANOVA; treatment: F(1,19) = 0.229, p = 0.63; time: F(1,19) = 2.096, p = 0.164; interaction: F(1,19) = 0.345, p = 0.56). C, HCN3 mRNA in 2W and 4W BLA (2-way ANOVA; treatment: F(1,16) = 0.84, p = 0.84; time: F(1,16) = 3.59, p = 0.08; interaction: F(1,16) = 1.73, p = 0.21). D, <t>HCN4</t> expression in 2W and 4W BLA. HCN4 expression was increased in 4W relative to 2W BLA in both Veh- and NPY-treated animals, but was not affected by NPY treatment (2-way ANOVA; treatment: F(1,15) = 1.24, p = 0.28; time: F(1,15) = 25.26, p = 0.0002; interaction: F(1,15) = 0.0083, p = 0.93). Data are shown as mean ± SEM; numbers of individual animals studied are indicated in each bar. *p < 0.05, **p < 0.01, Bonferroni's multiple-comparisons test; significantly different from 2W time point (Fig. 8A) or corresponding 2W group (Fig. 8D).
Rabbit Anti Hcn4, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti hcn4/product/Alomone Labs
Average 94 stars, based on 1 article reviews
rabbit anti hcn4 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cd140b antibody, anti-human, apc, reafinity  (Miltenyi Biotec)
94
Miltenyi Biotec cd140b antibody, anti-human, apc, reafinity
qRT-PCR measurements reveal downregulation of HCN1 expression in 4W NPY- versus 4W Veh-treated BLA. A, HCN1 mRNA expression in 2W and 4W BLA. HCN1 expression was significantly reduced in the BLA of NPY-treated animals at 4W (2-way ANOVA; treatment: F(1,19) = 4.592, p = 0.04; Time: F(1,19) = 1.348, p = 0.26; interaction: F(1,19) = 5.078, p = 0.03). B, HCN2 expression in 2W and 4W BLA (2-way ANOVA; treatment: F(1,19) = 0.229, p = 0.63; time: F(1,19) = 2.096, p = 0.164; interaction: F(1,19) = 0.345, p = 0.56). C, HCN3 mRNA in 2W and 4W BLA (2-way ANOVA; treatment: F(1,16) = 0.84, p = 0.84; time: F(1,16) = 3.59, p = 0.08; interaction: F(1,16) = 1.73, p = 0.21). D, <t>HCN4</t> expression in 2W and 4W BLA. HCN4 expression was increased in 4W relative to 2W BLA in both Veh- and NPY-treated animals, but was not affected by NPY treatment (2-way ANOVA; treatment: F(1,15) = 1.24, p = 0.28; time: F(1,15) = 25.26, p = 0.0002; interaction: F(1,15) = 0.0083, p = 0.93). Data are shown as mean ± SEM; numbers of individual animals studied are indicated in each bar. *p < 0.05, **p < 0.01, Bonferroni's multiple-comparisons test; significantly different from 2W time point (Fig. 8A) or corresponding 2W group (Fig. 8D).
Cd140b Antibody, Anti Human, Apc, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd140b antibody, anti-human, apc, reafinity/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd140b antibody, anti-human, apc, reafinity - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cd282 (tlr2) antibody, anti-human/mouse, apc, reafinity  (Miltenyi Biotec)
95
Miltenyi Biotec cd282 (tlr2) antibody, anti-human/mouse, apc, reafinity
qRT-PCR measurements reveal downregulation of HCN1 expression in 4W NPY- versus 4W Veh-treated BLA. A, HCN1 mRNA expression in 2W and 4W BLA. HCN1 expression was significantly reduced in the BLA of NPY-treated animals at 4W (2-way ANOVA; treatment: F(1,19) = 4.592, p = 0.04; Time: F(1,19) = 1.348, p = 0.26; interaction: F(1,19) = 5.078, p = 0.03). B, HCN2 expression in 2W and 4W BLA (2-way ANOVA; treatment: F(1,19) = 0.229, p = 0.63; time: F(1,19) = 2.096, p = 0.164; interaction: F(1,19) = 0.345, p = 0.56). C, HCN3 mRNA in 2W and 4W BLA (2-way ANOVA; treatment: F(1,16) = 0.84, p = 0.84; time: F(1,16) = 3.59, p = 0.08; interaction: F(1,16) = 1.73, p = 0.21). D, <t>HCN4</t> expression in 2W and 4W BLA. HCN4 expression was increased in 4W relative to 2W BLA in both Veh- and NPY-treated animals, but was not affected by NPY treatment (2-way ANOVA; treatment: F(1,15) = 1.24, p = 0.28; time: F(1,15) = 25.26, p = 0.0002; interaction: F(1,15) = 0.0083, p = 0.93). Data are shown as mean ± SEM; numbers of individual animals studied are indicated in each bar. *p < 0.05, **p < 0.01, Bonferroni's multiple-comparisons test; significantly different from 2W time point (Fig. 8A) or corresponding 2W group (Fig. 8D).
Cd282 (Tlr2) Antibody, Anti Human/Mouse, Apc, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd282 (tlr2) antibody, anti-human/mouse, apc, reafinity/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd282 (tlr2) antibody, anti-human/mouse, apc, reafinity - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


qRT-PCR measurements reveal downregulation of HCN1 expression in 4W NPY- versus 4W Veh-treated BLA. A, HCN1 mRNA expression in 2W and 4W BLA. HCN1 expression was significantly reduced in the BLA of NPY-treated animals at 4W (2-way ANOVA; treatment: F(1,19) = 4.592, p = 0.04; Time: F(1,19) = 1.348, p = 0.26; interaction: F(1,19) = 5.078, p = 0.03). B, HCN2 expression in 2W and 4W BLA (2-way ANOVA; treatment: F(1,19) = 0.229, p = 0.63; time: F(1,19) = 2.096, p = 0.164; interaction: F(1,19) = 0.345, p = 0.56). C, HCN3 mRNA in 2W and 4W BLA (2-way ANOVA; treatment: F(1,16) = 0.84, p = 0.84; time: F(1,16) = 3.59, p = 0.08; interaction: F(1,16) = 1.73, p = 0.21). D, HCN4 expression in 2W and 4W BLA. HCN4 expression was increased in 4W relative to 2W BLA in both Veh- and NPY-treated animals, but was not affected by NPY treatment (2-way ANOVA; treatment: F(1,15) = 1.24, p = 0.28; time: F(1,15) = 25.26, p = 0.0002; interaction: F(1,15) = 0.0083, p = 0.93). Data are shown as mean ± SEM; numbers of individual animals studied are indicated in each bar. *p < 0.05, **p < 0.01, Bonferroni's multiple-comparisons test; significantly different from 2W time point (Fig. 8A) or corresponding 2W group (Fig. 8D).

Journal: The Journal of Neuroscience

Article Title: NPY Induces Stress Resilience via Downregulation of I h in Principal Neurons of Rat Basolateral Amygdala

doi: 10.1523/JNEUROSCI.3528-17.2018

Figure Lengend Snippet: qRT-PCR measurements reveal downregulation of HCN1 expression in 4W NPY- versus 4W Veh-treated BLA. A, HCN1 mRNA expression in 2W and 4W BLA. HCN1 expression was significantly reduced in the BLA of NPY-treated animals at 4W (2-way ANOVA; treatment: F(1,19) = 4.592, p = 0.04; Time: F(1,19) = 1.348, p = 0.26; interaction: F(1,19) = 5.078, p = 0.03). B, HCN2 expression in 2W and 4W BLA (2-way ANOVA; treatment: F(1,19) = 0.229, p = 0.63; time: F(1,19) = 2.096, p = 0.164; interaction: F(1,19) = 0.345, p = 0.56). C, HCN3 mRNA in 2W and 4W BLA (2-way ANOVA; treatment: F(1,16) = 0.84, p = 0.84; time: F(1,16) = 3.59, p = 0.08; interaction: F(1,16) = 1.73, p = 0.21). D, HCN4 expression in 2W and 4W BLA. HCN4 expression was increased in 4W relative to 2W BLA in both Veh- and NPY-treated animals, but was not affected by NPY treatment (2-way ANOVA; treatment: F(1,15) = 1.24, p = 0.28; time: F(1,15) = 25.26, p = 0.0002; interaction: F(1,15) = 0.0083, p = 0.93). Data are shown as mean ± SEM; numbers of individual animals studied are indicated in each bar. *p < 0.05, **p < 0.01, Bonferroni's multiple-comparisons test; significantly different from 2W time point (Fig. 8A) or corresponding 2W group (Fig. 8D).

Article Snippet: The primary antibodies used were guinea pig guinea pig anti-HCN1 (1:2000; Alomone Laboratories, catalog #AGP-203), rabbit anti-HCN2 (1:1000; Alomone Laboratories, catalog #APC-030, RRID: AB_2313726 ), rabbit anti-HCN4 (1:2000; Alomone Laboratories, catalog #AGP-004, RRID: AB_2340957 ), mouse anti-TRIP8b exon4 (1:10,000; UC Davis/NIH NeuroMab Facility, catalog #73–208, RRID: AB_2162409 ), and mouse anti-βActin (1:20,000, Sigma-Aldrich, catalog #A5441, RRID: AB_476744 ).

Techniques: Quantitative RT-PCR, Expressing